1. Home
  2. QTTB vs XAIR Comparison

QTTB vs XAIR Comparison

Compare QTTB & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • XAIR
  • Stock Information
  • Founded
  • QTTB 2015
  • XAIR 2011
  • Country
  • QTTB United States
  • XAIR United States
  • Employees
  • QTTB N/A
  • XAIR N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • XAIR Medical/Dental Instruments
  • Sector
  • QTTB Health Care
  • XAIR Health Care
  • Exchange
  • QTTB Nasdaq
  • XAIR Nasdaq
  • Market Cap
  • QTTB 18.9M
  • XAIR 17.0M
  • IPO Year
  • QTTB N/A
  • XAIR N/A
  • Fundamental
  • Price
  • QTTB $1.44
  • XAIR $0.18
  • Analyst Decision
  • QTTB Hold
  • XAIR Strong Buy
  • Analyst Count
  • QTTB 8
  • XAIR 2
  • Target Price
  • QTTB $24.00
  • XAIR $1.50
  • AVG Volume (30 Days)
  • QTTB 123.8K
  • XAIR 5.4M
  • Earning Date
  • QTTB 08-07-2025
  • XAIR 08-05-2025
  • Dividend Yield
  • QTTB N/A
  • XAIR N/A
  • EPS Growth
  • QTTB N/A
  • XAIR N/A
  • EPS
  • QTTB N/A
  • XAIR N/A
  • Revenue
  • QTTB N/A
  • XAIR $3,705,000.00
  • Revenue This Year
  • QTTB N/A
  • XAIR $286.75
  • Revenue Next Year
  • QTTB N/A
  • XAIR $144.39
  • P/E Ratio
  • QTTB N/A
  • XAIR N/A
  • Revenue Growth
  • QTTB N/A
  • XAIR 219.67
  • 52 Week Low
  • QTTB $1.38
  • XAIR $0.15
  • 52 Week High
  • QTTB $53.79
  • XAIR $0.68
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 36.08
  • XAIR 47.34
  • Support Level
  • QTTB $1.41
  • XAIR $0.15
  • Resistance Level
  • QTTB $1.63
  • XAIR $0.29
  • Average True Range (ATR)
  • QTTB 0.11
  • XAIR 0.03
  • MACD
  • QTTB -0.02
  • XAIR -0.00
  • Stochastic Oscillator
  • QTTB 8.89
  • XAIR 19.29

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Share on Social Networks: